Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
15.95
+0.18 (1.14%)
At close: Nov 20, 2024, 4:00 PM
15.90
-0.05 (-0.31%)
Pre-market: Nov 21, 2024, 7:11 AM EST
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $12.50M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $16.00M.
Revenue (ttm)
$16.00M
Revenue Growth
n/a
P/S Ratio
81.86
Revenue / Employee
$86,957
Employees
184
Market Cap
1.36B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Evolent Health | 2.46B |
Guardian Pharmacy Services | 1.17B |
Myriad Genetics | 823.60M |
U.S. Physical Therapy | 639.06M |
BioCryst Pharmaceuticals | 412.58M |
Harrow | 169.14M |
Ocular Therapeutix | 61.44M |
Intellia Therapeutics | 43.09M |
SNDX News
- 5 days ago - US FDA approves Syndax's blood cancer drug - Reuters
- 5 days ago - Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation - PRNewsWire
- 8 days ago - Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity - Seeking Alpha
- 9 days ago - Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib - PRNewsWire
- 15 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update - PRNewsWire
- 15 days ago - Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 - PRNewsWire
- 15 days ago - Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting - PRNewsWire